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Summary 
Natural killer (NK) cells kill normal and transformed hematopoietic cells that lack expression 
of major histocompatibility complex (MHC) class I antigens. Lysis of HLA-negative Epstein 
Barr virus-transformed B lymphoblastoid call lines (B-LCL) by human NK cell clones can be 
inhibited by transfection ofthe target cells with certain HLA-A, -I3, or -C alleles. NK cell clones 
established from an individual demonstrate donal heterogeneity in HLA recognition and a single 
NK clone can recognize multiple alleles. We describe apotential human NK cell receptor (NKB1) 
for certain HLA-B alleles (e.g., HLA-B*5101 and-B*5801) identified by the mAb Dxg. NKB1 
is a 70-kD glycoprotein that is expressed on a subset of NK cells and NK cell clones. DX9 monoclonal 
antibody (mAb) specifically inhibits the interaction between NK cell clones and B-LCL targets 
transfected with certain HLA-B alleles, but does not affect recognition of HLA-A or HLA-C 
antigens. An individual NK cell clone can independently recognize B-LCL targets transfected 
with HLA-B or HLA-C antigens; however, DX9 mAb only affects interaction with transfectants 
expressing certain HLA-B alleles. These findings demonstrate the existence of NK cell receptors 
involved in the recognition of HLA-B and imply the presence of multiple receptors for MHC 
on an individual NK clone. 
N 'K cells are lymphocytes distinct from T and B cells that mediate cell-mediated cytotoxicity and secrete cytokines 
after immune stimulation (1). The specific receptors involved 
in NK cell recognition and activation remain undefined; 
nonetheless, it is becoming increasingly clear that both trig- 
gering and inhibitory molecules dictate their lytic specificity 
NK cell effector function presumably involves apositive signal 
that initiates cytotoxicity and cytokine production. In the 
case of antibody-dependent c llular cytotoxicity, the positive 
signal is generated by the interaction between the Ig-coated 
target and CD16 (Fc',/RIII) on the NK cell (2). The mem- 
brane receptors esponsible for initiating lysis of transformed 
or virus-infected cells in the absence of specific Ig have not 
been identified. 
NK cell-mediated cytotoxicity isalso regulated by inhibi- 
tory signals. K~"re et al. (3, 4) initially observed that certain 
murine tumor variants lacking H-2 antigens were more sus- 
ceptible to NK lysis than the parental tumor cells expressing 
high levels of H-2. Similarly, when MHC class I molecules 
were transfected into human HLA class I-deficient B lym- 
phoblastoid cell lines (B-LCL), 1 the transfectants were less 
1 Abbreviation used in this paper: B-LCL, B lymphoblastoid cell lines. 
susceptible toNK cell lysis than the parental lines (5, 6). Anal- 
ysis of an extensive panel of NK cell clones revealed that human 
NK cells have the ability to recognize multiple HLA-A, -B, 
and -C alleles (7). Two models that could account for this 
phenomenon have been proposed: (a) target interference and 
(b) effector inhibition (3, 4). The target interference model 
postulates that target cell MHC class I molecules mask an- 
tigens that stimulate NK lysis; the effector inhibition model 
proposes that target cell MHC class I molecules interact with 
specific receptors on NK cells, thereby transmitting a nega- 
tive signal that prevents the initiation of cytolysis. Recent 
findings support he latter model (8). 
Karlhofer et al. (8) have identified a class I MHC receptor, 
Ly-49, that is expressed on a subset ofmurine NK cells. The 
interaction between Ly-49 on the NK cell and H-2D a mol- 
ecules on target cells prevents NK cell-mediated cytotoxicity. 
Ly-49 is a type II membrane glycoprotein ofthe C-type lectin 
superfamily. Ly-49 and a family of at least five related genes 
are on mouse chromosome 6 (9-11). One member of the Ly- 
49 family, SWSE6, (12) appears to be involved in mediating 
the rejection of allogeneic bone marrow cells (13). SW5E6 
and Ly-49 are expressed as disulfide-linked homodimers; as
yet, there is no evidence for heterodimers between members 
of the Ly-49 family. Human NK cell receptors for HLA have 
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yet to be characterized fully, although Colonna et al. (14) 
and Ciccone et al. (15) describe two antigens expressed on 
NK subsets that appear to correlate with recognition of 
HLA-C. Our studies, however, have demonstrated that NK 
clones recognize not only HLA-C, but also HLA-A and 
HLA-B (7), suggesting the existence of additional receptors. 
In the present study, we describe an NK cell receptor involved 
in the recognition of HLA-B. 
Materials and Methods 
NK Clones. Peripheral blood from healthy individuals was pur- 
chased from the Stanford Blood Bank (Stanford, CA). NK cell clones 
(CD3-, CD56 +) were established using the culture conditions de- 
scribed by Yssel et al. (16). 
raAbs andFlow Cytometry. mAbs were provided generously b  
Becton Dickinson Immunocytometry Systems (Mountain View, 
CA). Cy-chrome TM conjugated anti-CD3 was purchased from 
PharMingen (San Diego, CA). The DX9 (IgG1) hybridoma was 
generated byimmunizing BALB/c mice with the human NK clone 
VL186-1 (CD3-, CD16 +, CD56 +) and fusing their splenocytes 
with the Sp2/0 myeloma cell line. Fab and F(ab')2 fragments were 
prepared by digesting DX9 IgG with immobilized papain (5 mg 
IgG in 5 ml of 20 mM NaHzPO~, 20 mM cysteine-HC1 buffer, 
pH 7.0, with 1 ml immobilized papain for 7 h at 37~ or im- 
mobilized pepsin (10 mg IgG in 10 ml of 0.2 M sodium citrate, 
0.15 M NaCI buffer, pH 3.5, with 2.5 ml immobilized pepsin for 
2 h at 37 ~ (Pierce, Rockford, IL), respectively, and afterwards 
removing residual intact mAb by protein A affinity chromatog- 
raphy. Purity of the F(ab')2 and Fab fragments was determined by
SDS-PAGE. Methods of immunofluorescent staining and flow 
cytometry have been described previously (17). 
Biochemistry. Cells were labded with nsI using lactoperoxi- 
dase/glucose oxidase or with [32p]orthophosphate (Amersham 
Corp., Arlington Heights, IL) (18). Cells were lysed in Tris-buffered 
saline (50 mM Tris, 15 mM NaCI, pH 8.0) containing 1% NP-40 
and protease inhibitors (1 mM PMSF and 20 Kallikrein inhibitor 
U/m1 aprotinin) and phosphatase inhibitors (1 mM EGTA, 10 mM 
NaF, 1 mM Na4PzO7, 0.1 mM ~-glycerophosphate, 1 mM 
Na3VO4) or 20 mM triethanolamine/150 mM NaCI buffer (pH 
7.8) containing 1% digitonin (CalBiochem-Novabiochem Corp., 
La Jolla, CA) and 0.12% Triton X-100 (Sigma Chemical Co., St. 
Louis, MO) with protease inhibitors. NKB1 antigen was immu- 
noprecipitated using the method escribed previously (18). NKB1 
glycoprotein was treated with neuraminidase (Sigma Chemical Co.), 
O-glycanase (Genzyme, Boston, /VIA), and N-glycosidase F 
(Boehringer Mannheim Corp., Indianapolis, IN) using the condi- 
tions recommended by the manufacturers. Samphs were analyzed 
by SDS-PAGE. 
Cytotoxicity Assays. NK cell-mediated cytotoxicity was mea- 
sured using a 4-h SlCr radioisotope r lease assay (2). Assays were 
performed using an effector/target ra io of 6:1 in the presence and 
absence of DX9 mAb (5/~g/ml). C1R B-LCL (19, 20) (HLA-A-, 
-B'3503 t~ -Cw*0401 +) and C1R transfectants expressing 
HLA-A'0201, -A*0301, -A'6801, -B'3701, and -B'5801 were 
provided generously b  Dr. Peter Cresswell (Yale University, New 
Haven, CT) and Dr. Jeffrey Dawson (Duke University, Durham, 
NC). 721.221 (HLA-A-, -B-, -C-) and 721.221.B'5101 and 
721.221.Cw*0301 transfectants were provided generously by Dr. 
Robert DeMurs (University of Wisconsin, Madison, WI) (21). 
721.221 transfectants expressing HLA-A*0201, -A*0211, -?,'3601, 
-B* 3505, -B'4801, -B* 5401, -B* 5501, -B* 5801, -Cw* 0102, 
-Cw*0304, -Cw*0401, -Cw*0801, and -Cw'1503 were generated 
as described previously (7). 
Results and Discussion 
Generation and Characterization f DX9 mAt~ Whereas 
many NK cell clones and polyclonal NK populations kill the 
MHC class I-deficient B-LCL C1R and 721.221, transfec- 
tion of these cell lines with certain alleles of HLA-A, -B, 
or -C results in protection from NK cell lysis (5, 6, 7). In 
particular, the products of certain HLA-B alleles (e.g., HLA- 
B'5101, -B'5801) frequently protected against lysis by NK 
clones (7). To identify NK call receptors for HLA, mAbs 
were generated against an NK done (VL186-1) that was 
strongly inhibited by the expression of HLA-B*5801 on the 
surface of the C1R B-LCL target (7). mAbs were therefore 
sdected for their capacity to permit lysis of the HLA-B*5801 
C1R transfectant and in this manner DX9 mAb was isolated. 
Whereas NK done VL186-1 failed to kill HLA-B*5801-trans- 
fected C1R (0% cytotoxicity), in the presence of mAb DX9 
64% lysis of HLA-B*5801-transfected CIR was observed. 
The DX9 mAb reacted with a molecule on the surface of 
NK done VL186-1, but failed to stain the HLA-B*5801 trans- 
fected C1R, indicating that the effect was due to interaction 
with the NK effector cell and not the target. 
The antigen recognized by DX9 mAb, designated NKB1, 
was found to be expressed on the surface of a subset of 
o 
Peripheral blood I: 
S 
Control Ig 
~es 
DX9 
B NK clone A4 NK clone B1 
~i  clg 
Figure 1. Expression f NKB1 on adult peripheral blood NK cells and 
NK cell clones. ( 4) Peripheral blood mononuclear cells were stained with 
FITC-conjugated anti-CD56 and PE-conjugated DX9 mAb or fluoro- 
chrome-conjugated control Ig. Samples were analyzed by flow cytometry. 
Lymphocytes were identified by their characteristic forward and side angle 
light scatter properties. Data are displayed ascontour plots (4 decade log 
scales). (B) NKB1 § and NKB1- NK cell clones were stablished by single 
cell cloning using flow cytometry. Representative NKB1- and NKB1 § 
NK clones were stained with PE-conjugated DX9 mAb or PE-conjugated 
control Ig (clg). Histograms of DX9 mAb-stained cells are superimposed 
over histograms of Ig control-stained c lls (nearest the ordinate). 
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CD3-, CD56 + NK cells isolated from peripheral blood 
(Fig. 1), but was not detected on the surface of granulocytes, 
monocytes, thymocytes, or B lymphocytes (not shown). Anal- 
ysis of peripheral blood from 18 normal adult donors indi- 
cated that NKB1 is present from <0.1 to 61% (mean = 14%) 
of CD3-,  CD56 + NK cells. The significance of this con- 
siderable heterogeneity is unknown. NKB1 was observed in- 
frequently on adult peripheral blood CD3 § lymphocytes, al- 
though a minor subset of NKB1 + T cells (<0.1-3%) could 
be detected in certain individuals (not shown). A panel of 
NKB1 - and NKB1 + NK clones (all of these were CD3-,  
CD56 + cells) were established by single cell doning using 
flow cytometry for further analysis. In all cases, the NKB1 
phenotype of the clones remained stable (representative clones 
are shown in Fig. 1). We have never observed acquisition of 
NKB1 by NK clones initially isolated as being NKB1- or 
the loss of NKB1 from NKB1 + NK clones. 
HIM Specificity of NKB1. NK clones were established from 
two donors on the basis of NKB1 expression (CD3-, 
CD56 +, NKB1 + and CD3-,  CD56 +, NKB1 -). Of the 29 
NKB1 + NK clones examined, all lysed HLA-deficient EBV 
transformed B-LCL C1R and demonstrated iminished lytic 
activity against HLA-B*5801 C1R transfectants. Cytolysis 
by NKB1 + NK clones against the HLA-B*5801 transfectant 
was augmented in the presence of DX9 mAb (Fig. 2 and 
Table 1). By contrast, killing of the untransfected HLA- 
deficient EBV transformed B-LCL cell lines 721.221 and C1R 
by NKB1 + NK clones was neither augmented nor inhibited 
by DX9 mAb (Fig. 2). As shown in Fig. 3, F(ab')2 and Fab 
fragments of the DX9 mAb, like the intact antibody, were 
able to permit lysis of the HLA-B*5801-transfected 721.221 
target cell. 
Examination of a panel of transfectants expressing different 
class I HLA genes indicated that DX9 mAb permitted cyto- 
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Figure 2. The effect of DX9 mAb on the ability of NK clones to lyse HLA-deficient or HLA-transfected B-LCL target cells. Two representative 
NKB1 + NK clones A4 and 47 were assayed for cytotoxicity against 721.221, C1R, or the indicated HLA transfectants in the presence (st@ed Mrs) 
or absence (solid bars) of DX9 mAb (5/*g/ml). The E/T ratio was 6:1. 
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F igure  3. Effect of F(ab')2 and Fab fragments of DX9 mAb on the 
ability of NKB1 + NK clone A13 to lyse HLA-B* 5801-transfected 721.221 
target calls. NKB1 + NK done A13 was assayed for cytotoxicity against 
HLA-B* 5801-transfected 721.221 target cells in the presence of intact DX9 
mAb (diamonds), DX9 F(ab')2 fragments (circles), and DX9 Fab fragments 
(triangles) as indicated. Anti-CD56 (Leu 19) mAb (squares) was used as 
the control Ig. Leu 19 is a murine IgG1 mAb that binds to all NK cells, 
but does not affect NK cell function. All mAb were used at 5/~g/ml and 
were added to the NK cells immediately before addition of the target calls. 
tox ic i ty  against  certa in HLA-B  alleles, in add i t ion  to HLA-  
B '5801,  but  d id not  affect cy to tox ic i ty  aga inst  any of  the  
HLA-C  transfectants examined.  Representat ive data obta ined 
f rom exper iments  w i th  two  NKB1 + dones  are shown in 
Fig, 2 and the  results  obta ined  f rom several NKB1-  and  
NKB1 + NK clones are summar ized  in Table 1. Whereas  
NKB1 + NK c lones recogn ized  and  therefore  fai led to lyse 
t ransfectants  express ing certa in  HLA-C  alleles, inc lud ing  
-Cw*0102,  Cw*0301,  -Cw*0304,  -Cw*0401,  -Cw*0801,  and 
-Cw'1503,  the  presence of  DX9 mAb had no  effect on  the  
target  p ro tect ion  confer red by  these molecules.  Th is  obser-  
vat ion demonstrates  that  b ind ing  DX9 mAb to the NK clones 
need not  inter fere w i th  the recogn i t ion  of  all HLA mole -  
cules, but  on ly  that  o f  specific alleles. 
Ind iv idua l  NK  c lones have the abi l i ty  to recogn ize  mul -  
t ip le alleles o f  HLA-B  (7). Therefore ,  we  examined the effect 
of  DX9 mAb on  NK ce l l -med ia ted  lysis of  B -LCL  t rans-  
The DX9 mAb and its F(ab')2 and Fab fragments did not affect NK cell- 
mediated lysis of the HLA-negative 721.221 EBV-LCL target cells (Fig, 
2 and not shown). 
Tab le  1. Lysis of HLA Transfected Target Cells in the Presence and Absence of DX9 mAb 
Cl tL  transfectants 721.221 transfectants 
B '3701 B '5801 B '5101 Cw*0301 Cw*0304 Cw*0401 
NK No No No No No No 
clone mAb DX9 mAb DX9 mAb DX9 mAb DX9 mAb DX9 mAb DX9 
DX9 § NK clones 
A4 + * + -+ + - + . . . . . .  
A6 + + - + - + + + nd nd ndS nd 
A7 + + - + - + . . . . . .  
A9 - - - + - + + + + + - - 
A21 + + - + - + + + + + - - 
A23 + + - + - + . . . .  + + 
A26 + + - + - + . . . . . .  
A36 - - - + - + - - nd nd nd nd 
DX9-  NK clones 
B1 + + - - + + . . . . . .  
B2 . . . .  + + + + + + - - 
B5 + + . . . . . . . . . .  
B6 + + - - + + + + nd nd nd nd 
B12 + + - - + + + + + + - - 
B19 + + - - + + + + nd nd nd nd 
* + Indicates that the percent specific lysis of the HLA-transfected target cell was comparable with that of the parental cell line or substantially 
increased in the presence ofDX9 mAb. In all cases the lysis of the parental cell lines was 30% or greater. The data are a composite of several experiments. 
+ - Indicates that the percent specific lysis of the HLA-transfected target cell was 50% or less than that of the parental cell line, i.e., the NK clone 
recognizes that particular HLA allele. 
s nd, not determined. 
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fectants expressing B*0702, -B'2705, -B'3505, -B'3701, 
-B'4801, -B'5101, -B'5401, or -B'5501. We observed that 
DX9 mAb reversed the protection conferred by HLA-B*5101 
consistently, in addition to HLA-B*5801 (Fig. 2 and Table 
1). The DX9 mAb also affected recognition of HLA-B*2705. 
However, the protection conferred by -B'2705 was less than 
with -B'5101 or -B'5801 (Fig. 2). Consistent with previous 
observations (7), NK clones recognizing -B*0702, -B'3505, 
-B'3701, -B'4801, -B'5401, or -B'5501 and the HLA-A al- 
leles (-A*0201, -A*0211, -A*0301, -A'3601, -A'6801) were 
less frequent than NK clones recognizing -B'5801; however, 
preliminary studies indicate that DX9 mAb has little effect 
upon the lysis of the latter transfectants (not shown). Fur- 
ther analysis of NK clones that recognize these less frequently 
protective HLA-A and HLA-B alleles is required to exclude 
reactivity with these molecules. 
Certain NKB1- NK cell clones recognized HLA-B* 5801 
and -B'5101, although as expected DX9 mAb failed to affect 
lysis of these transfectants. Therefore, whereas the results are 
compatible with the possibility that NKB1 is a receptor for 
HLA-B*5801 and -B'5101, they also suggest that additional 
receptors with this specificity are also present on NKB1- 
NK clones. NKB1 - NK clones may express a variant of the 
NKB1 molecule not recognized by the DX9 mAb or a dis- 
tinct receptor that also recognizes HLA-B*5801 and -B'5101. 
There was no apparent bias in the recognition of HLA-A 
or HLA-C alleles by clones derived from either the NKB1- 
or NKB1 + NK subsets, suggesting the existence of indepen- 
dent receptors for HLA-A and HLA-C. 
Structure of NKB1 Antigen. The DX9 mAb immuno- 
precipitates a 70-kD glycoprotein from 12SI-labeled NKB1 + 
NK cell clones that on SDS-PAGE gels migrates as a single 
species under both reducing and nonreducing conditions (Fig. 
4). Identical results were obtained using 1% NP-40 or 1% 
digitonin detergent for cell disruption. Treatment with neur- 
aminidase slightly decreased the mobility of NKB1, indicating 
that the protein is sialated. Digestion of the NKB1 protein 
with Noglycanase r duced the apparent molecule weight to 
"~50 kD, demonstrating the presence of complex N-linked 
olignsaccharides. In contrast, endo-H and O-glycanase had 
no effect upon the mobility of the NKB1 protein. Immuno- 
precipitation from NK cell clones metabolically abeled with 
[32p]orthophosphate indicated that NKB1 is phosphorylated. 
Stimulation with PMA neither increased nor decreased phos- 
phorylation of NKB1. 
Conclusions. Analysis of the specificity of NK clones against 
a panel of target cells transfected with class I MHC mole- 
cules argues strongly that distinct receptors for individual 
HLA alleles or groups of HLA alleles are expressed by human 
NK cells. Our results support the possibility that NKB1 
represents one such receptor that is specific for certain HLA-B 
alleles, although formal proof requires evidence for the direct 
interaction of NKB1 and HLA-B molecules. Several obser- 
vations suggest hat NK cell recognition of HLA is com- 
plex. An individual NK clone can recognize HLA-A, -B, and 
-C molecules. Whereas NKB1 + NK clones all recognize 
HLA-B*5801, these clones demonstrate heterogeneous rec- 
Figure 4. Structure ofNKB1. (A) NKBI* NK clones were lz~I-labeled 
and lysed in 1% NP-40. Lysates were immunoprecipitated with control 
Ig or DX9 mAb and samples analyzed by SDS-PAGE in the presence or
absence of2-mercaptoethanol. (B) ZSl NKB1 antigen was treated with 
neuraminidase, O-glycanase, endo H, or N-glycanase, asindicated, and 
analyzed by SDS-PAGE in the presence of2-mercaptoethanol. (C) NKB1 § 
NK clones were metabolically labeled with[32P]orthophosphate and were 
then stimulated ornot with 1 ng/ml PMA for 5 rain. Cells were lysed 
in 1% NP-40, lysates were immunoprecipitated with control Ig, anti- 
HLA-A, -B, -C mAbs (positive control) or DX9 mAb and samples ana- 
lyzed by SDS-PAGE in the presence of2-mercaptoethanol. 
ognition of different HLA-C molecules, implying the exis- 
tence of multiple NK receptors. Some NKB1- NK clones 
were also functionally inhibited by HLA-B*5801, indicating 
the presence of another HLA-B*5801 receptor on the 
NKB1- subset. Moreover, NKB1 appears to recognize 
HLA-B*5801, -B'5101, and possibly -B'2705. 
It should be noted that NKB1 + NK clones shown in Fig. 
2 were derived from an HLA-B*5801 + donor. Thus, both 
the NKB1 receptor and its putative ligand HLA-B* 5801 can 
be expressed by the same NK done. Moreover, NKB1 + NK 
clones from an HLA-B*5801 + donor efficiently lysed the 
HLA-deficient B-LCL CIR, whereas no lysis of C1R.B*5801 
was observed. These results indicate that if a "negative signal" 
is induced it is directional and target specific (i.e., the poten- 
tial interaction of NKB1 with HLA-B on either the same 
or an adjacent NK clone does not prevent he lysis of a sus- 
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ceptible target lacking HLA class I molecules). Therefore, 
the putative inhibitory signal sent through the NKB1 receptor 
does not irreversibly inactivate the NK cell. Recent studies 
using NK cell lines reactive with HLA-C also support he 
concept hat bystander cells expressing inhibitory HLA al- 
leles are unable to affect he interaction between an NK cell 
and a susceptible target (22). 
Further heterogeneity is introduced by the expression of 
NKB1 on only a subset of NK cells and the variable size of 
this subset in different individuals. A similar situation exists 
with expression of Ly-49 and 5E6, which are expressed only 
on a subset of NK cells in certain mouse strains (9, 13). Simi- 
larly, the EB6 and GL183 antigens implicated in recognition 
of HLA-C are expressed only on partially overlapping subsets 
of human NK cells (23). 
Previous tudies by Colonna et al. (14) have demonstrated 
a correlation between expression of EB6 and GL183 and target 
cell protection by HLA-C. From family studies and analysis 
of HLA-C transfectants, two NK target specificities (desig- 
nated group 1 and group 2) corresponding to a dimorphic 
sequence motif at amino acids 77 and 80 of HLA-C alleles 
have been defined (14, 22, 24). The NKB1 molecule is dis- 
tinct both in class I HLA specificity and structure from EB6 
and GL183. Certain NKB1 + NK clones have the ability to 
recognize HLA-C alleles of the group 1 or 2 specificities. 
EB6/GL183 and NKB1 are all structurally different from the 
murine Ly-49 receptors, which are disulfide-linked homodimers 
(9). Furthermore, the 70-kD NKB1 glyeoprotein appears larger 
on SDS-PAGE than the EB6 and GL183 glycoprotdns, which 
migrate at 58 kD. Further understanding of the relationship 
between these various NK receptors will come from com- 
parison of the sequences of the cloned genes. Nonethdess, 
the results are compatible with the existence of distinct NK 
receptors for HLA-B and HLA-C on a single NK done that 
function independently. 
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